Muraglitazar

Muraglitazar
	File:Muraglitazar.png
Identifiers
	IUPAC name 2-[(4-Methoxyphenoxy)carbonyl-[ [4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid;
CAS Number	331741-94-7;
PubChem CID	206044;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C29H28N2O7
Molar mass	516.54
3D model (JSmol)	Interactive image;
	SMILES CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3= CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC;

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Muraglitazar (proposed tradename Pargluva) is a peroxisome proliferator-activated receptor agonist.^[1]

The drug had completed phase III clinical trials,^[2] however in May, 2006 Bristol-Myers Squibb announced that it had discontinued further development.^[3]

References

↑ Waites CR, Dominick MA, Sanderson TP, Schilling BE (2007). "Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist". Toxicol. Sci. 100 (1): 248–58. doi:10.1093/toxsci/kfm193. PMID 17675651.
↑ Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA (2006). "Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study". Diabetes Care. 29 (5): 1016–23. doi:10.2337/diacare.2951016. PMID 16644631.
↑ "Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes". Bristol-Myers Squibb. 2006-05-18. Retrieved 2008-03-18.

Template:Oral hypoglycemics

Template:Pharma-stub

[pmid17675651-1] Waites CR, Dominick MA, Sanderson TP, Schilling BE (2007). "Nonclinical safety evaluation of muraglitazar, a novel PPARalpha/gamma agonist". Toxicol. Sci. 100 (1): 248–58. doi:10.1093/toxsci/kfm193. PMID 17675651.

[pmid16644631-2] Kendall DM, Rubin CJ, Mohideen P, Ledeine JM, Belder R, Gross J, Norwood P, O'Mahony M, Sall K, Sloan G, Roberts A, Fiedorek FT, DeFronzo RA (2006). "Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study". Diabetes Care. 29 (5): 1016–23. doi:10.2337/diacare.2951016. PMID 16644631.

[Muraglitazar_press_release-3] "Bristol-Myers Squibb Announces Discontinuation of Development of Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes". Bristol-Myers Squibb. 2006-05-18. Retrieved 2008-03-18.

[1]

[2]

[3]

Identifiers
File:Muraglitazar.png
IUPAC name 2-[(4-Methoxyphenoxy)carbonyl-[ [4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]amino]acetic acid
CAS Number	331741-94-7
PubChem CID	206044
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₉H₂₈N₂O₇
Molar mass	516.54
3D model (JSmol)	Interactive image
SMILES CC1=C(N=C(O1)C2=CC=CC=C2)CCOC3= CC=C(C=C3)CN(CC(=O)O)C(=O)OC4=CC=C(C=C4)OC

Muraglitazar

References

Navigation menu